Canada markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
323.48+10.02 (+3.20%)
At close: 04:03PM EDT
324.60 +1.12 (+0.35%)
After hours: 07:59PM EDT
Sign in to post a message.
  • R
    Rick
    Hope to sell Lilly this year to buy a new home. I will miss owning the stock as it has been a great investment. I'm a 30+ year long and invested the dividend the entire time. I also put in an occasional extra $1 or $2k every couple of years if I could afford it. Now for what has been a modest initial investment of 30k along with the dividend and extra small add on the stock has grown to over 600k, with which I will buy a new home. Not bad for a poor boy who didn't graduate college or received an inheritance to speak of. Thank you Lilly for being a good, solid company that saves lives, promotes health and makes investors well off.
  • A
    Anonymous
    I know healthcare/pharma isn't impacted by economic slowdowns, the same way as other sectors, but valuation has to be taken into account. Staples stocks were safe until last week. I know pharma stocks don't have that same economic concern. I know LLY deserves a higher valuation based on it's growth, but still, are any of you who own or are looking to own LLY have any valuation concerns? I don't want to buy the weak sectors, which are pretty much all of them, outside of Energy, Healthcare, and Utilities, but I don't want to buy into a hot sector at the top. Just seems like LLY is doing great. But if the market wants to int can punish healthcare/LLY too. With LLY's valuation it could really go down. Seems it's had too much good news and good fundamentals to drop, so far.
  • B
    Bombastic
    (BIVI) MC $71 million // 3x Blockbusters in Pipeline targeting Alzheimer Disease (Phase 3 data in mid 2023) and Parkinsons Disease (Phase 2 data coming this quarter) Slide Presentation below =10 Bagger opp
    https://bioviepharma.com/wp-content/uploads/2022/04/BioVie-Company-Overview-2022-04-13.pdf

    ###
  • M
    MidWestInvestm2
    This is going to 400
  • A
    A
    Should raise dividends end of year
  • C
    Crecy
    Buy B4 $300
  • C
    Crecy
    Adding a few shares.
  • d
    demetrios
    It might go to 400
  • T
    Thomas
    wow up $24 in last 5 days. bought 5 days ago and going to park position forever reinvest dividends
  • J
    John
    I trimmed 10 shares at 300 and looking to trim 5 more at 320. Stock is trading at 20 p/e for 2024.

    I keep all my non IRA shares but trim my IRA shares.
  • M
    MidWestInvestm2
    Maybe the best biotech performer this year so far.
  • T
    Thomas
    bought 10 shares down $2. rallied up $4 first day. place you can hide out
  • G
    Gerry
    Eric and Anonymous......need to find a new line of work?
  • R
    Rick
    Thank you Lilly for continuing to be a great company for health and for investment. Buy and hold and reinvest the dividend and presto after 30 years you'll become a millionaire. It happened to me and I don't care if anyone believes it or not.
  • W
    William
    fantastic Rick.....hoping to pull some out to buy a car and live with the long covid effects
  • P
    Pro Portfolio Manager
    Very good news for COVID patient and for LLY.
  • B
    Brian
    Take . Theya look at ticker symbol ILUS, ILUS International also. Drones, UAVs and EVs. They also hold patented firefighting technology. ILUS has just entered into huge deal with the European Union, which will be supporting the defense sector and well as the private sector. They are undervalued and very profitable for being less than two years old. Certianly worth a look. ILUS - ILUS International. Have a good rest of your weekend and week,
  • D
    Davebiotech
    Anyone hear pricing for new diabetes drug? Merck's Victoza is $1200 per month for one shot.
  • B
    Burrill
    I hope LLY is following SAVA as they appear to have a drug that successfully treats Alzheimer’s disease in a novel way. Could be a smart purchase for LLY. As a long time LLY shareholder I recently started accumulating shares of SAVA,
    ,
  • D
    Dimitar
    It is simply way overvalued. For fiscal 22 they need to make 10 B in Free Cash Flow and grow with pace of 13 % for the next 5 years and 8 % for another 5 in order to justify these price levels. Could they make it? Short answer yes. Is it possible in the real world.. meh . Better put a bigger margin of safety and buy below 164 and dollar cost average on the way down.

    Glaxo (GSK) is in the same sector and have way better stats/value than (LLY).

    This is not financial advise, it's just what numbers say and how much LLY needs to make in order to worth 292 $ at todays market open.